233 related articles for article (PubMed ID: 36535465)
1. Development of an inhaled anti-TSLP therapy for asthma.
O'Byrne PM; Panettieri RA; Taube C; Brindicci C; Fleming M; Altman P
Pulm Pharmacol Ther; 2023 Feb; 78():102184. PubMed ID: 36535465
[TBL] [Abstract][Full Text] [Related]
2. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
Gauvreau GM; Hohlfeld JM; FitzGerald JM; Boulet LP; Cockcroft DW; Davis BE; Korn S; Kornmann O; Leigh R; Mayers I; Watz H; Grant SS; Jain M; Cabanski M; Pertel PE; Jones I; Lecot JR; Cao H; O'Byrne PM
Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36822634
[TBL] [Abstract][Full Text] [Related]
3. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
4. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.
Gauvreau GM; Sehmi R; Ambrose CS; Griffiths JM
Expert Opin Ther Targets; 2020 Aug; 24(8):777-792. PubMed ID: 32567399
[TBL] [Abstract][Full Text] [Related]
5. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani P; Manzetti GM; Bettin FR; D'Auria M; Calzetta L
Expert Opin Investig Drugs; 2024 Jan; 33(1):39-49. PubMed ID: 38206116
[TBL] [Abstract][Full Text] [Related]
6. Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma.
Cheng DT; Ma C; Niewoehner J; Dahl M; Tsai A; Zhang J; Gonsiorek W; Apparsundaram S; Pashine A; Ravindran P; Jung J; Hang J; Allard J; Bitter H; Tribouley C; Narula S; Wilson S; Fuentes ME
J Allergy Clin Immunol; 2013 Aug; 132(2):455-62. PubMed ID: 23810153
[TBL] [Abstract][Full Text] [Related]
7. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R; Lugogo N; Corren J; Ambrose CS
J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
[TBL] [Abstract][Full Text] [Related]
8. Severe Asthmatic Responses: The Impact of TSLP.
Theofani E; Tsitsopoulou A; Morianos I; Semitekolou M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108740
[TBL] [Abstract][Full Text] [Related]
9. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
[No Abstract] [Full Text] [Related]
10. Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
Nakajima S; Kabata H; Kabashima K; Asano K
Allergol Int; 2020 Apr; 69(2):197-203. PubMed ID: 31974038
[TBL] [Abstract][Full Text] [Related]
11. Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.
Lin SC; Cheng FY; Liu JJ; Ye YL
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670037
[TBL] [Abstract][Full Text] [Related]
12. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
Shinkai M; Yabuta T
Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
[TBL] [Abstract][Full Text] [Related]
13. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD.
Calderon AA; Dimond C; Choy DF; Pappu R; Grimbaldeston MA; Mohan D; Chung KF
Eur Respir Rev; 2023 Mar; 32(167):. PubMed ID: 36697211
[TBL] [Abstract][Full Text] [Related]
14. T cell-mediated induction of thymic stromal lymphopoietin in differentiated human primary bronchial epithelial cells.
Hui CC; Murphy DM; Neighbour H; Al-Sayegh M; O'Byrne S; Thong B; Denburg JA; Larché M
Clin Exp Allergy; 2014 Jul; 44(7):953-64. PubMed ID: 24773145
[TBL] [Abstract][Full Text] [Related]
15. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M; Kabata H; Irie M; Fukunaga K
Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
[TBL] [Abstract][Full Text] [Related]
16. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.
Gauvreau GM; O'Byrne PM; Boulet LP; Wang Y; Cockcroft D; Bigler J; FitzGerald JM; Boedigheimer M; Davis BE; Dias C; Gorski KS; Smith L; Bautista E; Comeau MR; Leigh R; Parnes JR
N Engl J Med; 2014 May; 370(22):2102-10. PubMed ID: 24846652
[TBL] [Abstract][Full Text] [Related]
17. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-Derived Cytokines in Asthma.
Mitchell PD; O'Byrne PM
Chest; 2017 Jun; 151(6):1338-1344. PubMed ID: 27818325
[TBL] [Abstract][Full Text] [Related]
19. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
20. Targeting TSLP in Asthma.
Parnes JR; Molfino NA; Colice G; Martin U; Corren J; Menzies-Gow A
J Asthma Allergy; 2022; 15():749-765. PubMed ID: 35685846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
